Drug Profile
KiroVAX 002
Alternative Names: BSK01; KiroVAX/BSK01; KiroVAX002; TAPA loaded DC vaccine - KiroVAX-002; TAPA loaded dendritic cell vaccine - KiroVAX-002; TAPA pulsed dendritic cell vaccine - KiroVAX-002; TAPA-pulsed DC vaccine - KiroVAX-002; Tumour associated peptide antigen loaded DC vaccine-KiroVAX-002; Tumour associated peptide antigen loaded dendritic cell vaccine - KiroVAX-002; Tumour associated peptide antigen pulsed DC vaccine - KiroVAX-002; Tumour associated peptide antigen pulsed dendritic cell vaccine - KiroVAX-002Latest Information Update: 03 Nov 2021
Price :
$50
*
At a glance
- Originator Kiromic
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Haematological malignancies
- Phase I Pancreatic cancer; Solid tumours
Most Recent Events
- 25 Oct 2021 Phase-I clinical trials in Pancreatic cancer (Metastatic disease, Combination therapy) (Parenteral) before October 2021
- 25 Oct 2021 Phase-I clinical trials in Solid tumours (Combination therapy) (Parenteral) before October 2021
- 25 Oct 2021 Efficacy data from a pilot phase I trial in Pancreatic cancer released by Kiromic Biopharma